Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Manufacturers such as Nestle have responded, debuting its Vital Pursuit brand specifically designed to support GLP-1 consumer diets. The frozen food products initially launched in September and ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...